Molecularly Targeted Therapies for Gastric Cancer. State of the Art.

ABSTRACT: Many phase III trials failed to demonstrate a survival benefit from the addition of molecular therapy to conventional chemotherapy for advanced and metastatic gastric cancer, and only three agents were approved by the FDA. We examined the efficacy and safety of novel drugs recently investigated. PubMed, Embase and Cochrane Library were searched for phase III randomized controlled trials published from January 2016 to December 2020. Patients in the experimental arm received molecular therapy with or without conventional chemotherapy, while those in the control arm had conventional chemotherapy alone. The primary outcomes were overall and progression-free survival. The secondary outcomes were the rate of tumor response, severe adverse effects, and quality of life. Eight studies with a total

SUBMITTER: Reddavid R 

PROVIDER: S-EPMC8392056 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature